ストックスクリーナーアプリを入手
11.53
1.50%
0.21
アフターアワーズ：
11.53
前日終値:
$11.32
開ける：
$11.27
24時間の取引高:
753.93K
Relative Volume:
0.44
時価総額：
$684.69M
収益：
$122.29M
当期純損益:
$122.31M
株価収益率:
5.3531
EPS:
2.1539
ネットキャッシュフロー:
$12.00M
1週間 パフォーマンス:
+0.08%
1か月 パフォーマンス:
-10.03%
6か月 パフォーマンス:
+33.75%
1年 パフォーマンス:
+21.84%
1日の値動き範囲:
$11.18
$11.58
1週間の範囲:
$10.81
$11.60
52週間の値動き範囲:
$7.16
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Compare ZVRA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
11.53 | 672.22M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | BTIG Research | Buy |
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - marketbeat.com
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - accessnewswire.com
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: A Biotech Stock with 113% Potential Upside - DirectorsTalk Interviews
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review? - Yahoo Finance
ZVRA Maintained by Citizens -- Price Target Raised to $28.00 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect - accessnewswire.com
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings - marketbeat.com
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure - Stock Titan
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside - TradingView
Zevra Therapeutics Q2 Earnings Call Highlights - MarketBeat
Citizens Jmp Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - marketbeat.com
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights - GuruFocus
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... - Yahoo Finance
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54 - GuruFocus
Earnings call transcript: Zevra beats Q2 2026 estimates as MIPLYFFA sales rise - Investing.com
ZVRA Looks 54.4% Undervalued on GF Value™ as Market Weighs Q2 Re - GuruFocus
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results - MarketBeat
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat - Quiver Quantitative
ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary - TradingView
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt - Stock Titan
Zevra Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales - TradingView
Zevra Reports Q2 2026: $39.7M Revenue, $8.8M Net Income, $260.2M Cash - TradingView
Zevra Therapeutics, Inc. (ZVRA) Q2 FY2026 earnings call transcript - Yahoo Finance
Press Release: Zevra Reports Second Quarter 2026 Financial Results and Corporate Update - Moomoo
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(ZVRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
Zevra Therapeutics Inc (ZVRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Watton Corey Michael | Director |
Aug 10 '26 |
Option Exercise |
4.97 |
12,300 |
61,131 |
14,100 |
| Watton Corey Michael | Director |
Aug 10 '26 |
Sale |
11.25 |
12,300 |
138,377 |
1,800 |
2.20%
0.07%
大文字化:
|
ボリューム (24 時間):